CL2019000914A1 - Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico. - Google Patents

Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.

Info

Publication number
CL2019000914A1
CL2019000914A1 CL2019000914A CL2019000914A CL2019000914A1 CL 2019000914 A1 CL2019000914 A1 CL 2019000914A1 CL 2019000914 A CL2019000914 A CL 2019000914A CL 2019000914 A CL2019000914 A CL 2019000914A CL 2019000914 A1 CL2019000914 A1 CL 2019000914A1
Authority
CL
Chile
Prior art keywords
treat
prevent
cirrhotic
fibrotic
compositions
Prior art date
Application number
CL2019000914A
Other languages
English (en)
Inventor
Andreas Bauer
Patrick Mueller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019000914A1 publication Critical patent/CL2019000914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN AGONISTA DEL RECEPTOR FARNESOIDE X (FXR) Y OTRO AGENTE TERAPÉUTICO, EN PARTICULAR, PARA TRATAR O PREVENIR ENFERMEDADES O TRASTORNOS HEPÁTICOS.
CL2019000914A 2016-10-05 2019-04-04 Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico. CL2019000914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404303P 2016-10-05 2016-10-05

Publications (1)

Publication Number Publication Date
CL2019000914A1 true CL2019000914A1 (es) 2019-06-14

Family

ID=60262958

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000914A CL2019000914A1 (es) 2016-10-05 2019-04-04 Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.

Country Status (15)

Country Link
US (1) US20190231770A1 (es)
EP (1) EP3522883A1 (es)
JP (1) JP2019530696A (es)
KR (1) KR20190062501A (es)
CN (1) CN109789119A (es)
AR (1) AR109809A1 (es)
AU (1) AU2017339826A1 (es)
BR (1) BR112019005985A2 (es)
CA (1) CA3039283A1 (es)
CL (1) CL2019000914A1 (es)
IL (1) IL265817A (es)
MX (1) MX2019003889A (es)
RU (1) RU2019113150A (es)
TW (1) TW201815420A (es)
WO (1) WO2018065902A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093705A (zh) * 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
US20220047553A1 (en) * 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
AU2020312734A1 (en) * 2019-07-18 2022-01-20 Enyo Pharma Improved treatment using EYP001
WO2021053618A1 (en) * 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
US20220331341A1 (en) * 2019-09-30 2022-10-20 Novartis Ag Treatment comprising the use of fxr agonists
CN113244281B (zh) * 2021-06-09 2022-11-01 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6559304B1 (en) 1998-08-19 2003-05-06 Vertex Pharmaceuticals Incorporated Method for synthesizing caspase inhibitors
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
EP1163208B1 (en) 1999-08-06 2004-05-12 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6790989B2 (en) 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
AU4961901A (en) 2000-03-29 2001-10-08 Vertex Pharma Carbamate caspase inhibitors and uses thereof
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
ATE510837T1 (de) 2000-09-13 2011-06-15 Vertex Pharma Caspase inhibitoren und deren verwendung
US6665495B1 (en) 2000-10-27 2003-12-16 Yotta Networks, Inc. Non-blocking, scalable optical router architecture and method for routing optical traffic
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
EP1539701A1 (en) 2002-06-28 2005-06-15 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
NZ549665A (en) 2004-02-27 2010-09-30 Vertex Pharma Caspase inhibitors and uses thereof
JP2005319019A (ja) 2004-05-07 2005-11-17 Bridgestone Sports Co Ltd ゴルフクラブヘッド
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
NZ719078A (en) * 2013-11-05 2018-07-27 Novartis Ag Compositions and methods for modulating farnesoid x receptors
RU2017125365A (ru) * 2014-12-18 2019-01-21 Новартис Аг Производные азабициклооктана в качестве агонистов fxr для применения при лечении заболеваний печени и желудочно-кишечных заболеваний
BR112018013558A2 (pt) * 2015-12-31 2018-12-04 Conatus Pharmaceuticals Inc método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada
JP6941109B2 (ja) * 2016-02-22 2021-09-29 ノバルティス アーゲー Ｆｘｒアゴニストを使用するための方法

Also Published As

Publication number Publication date
IL265817A (en) 2019-06-30
BR112019005985A2 (pt) 2019-06-25
WO2018065902A1 (en) 2018-04-12
RU2019113150A (ru) 2020-11-06
TW201815420A (zh) 2018-05-01
EP3522883A1 (en) 2019-08-14
MX2019003889A (es) 2019-08-12
AU2017339826A1 (en) 2019-04-04
KR20190062501A (ko) 2019-06-05
CA3039283A1 (en) 2018-04-12
AR109809A1 (es) 2019-01-23
CN109789119A (zh) 2019-05-21
JP2019530696A (ja) 2019-10-24
US20190231770A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
BR112018005777A2 (pt) anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018003502A1 (es) Métodos para tratar la osificación heterotópica.
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina